Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This double blind, randomized phase II trial will investigate whether the addition of
tocotrienol will improve the effect and lower the toxicity of standard chemotherapy and
bevacizumab. Half of the patients will receive tocotrienol and the other half placebo.
Treatment is planned for a period of maximum six months and will be discontinued earlier in
case of progression or unacceptable toxicity.